Investor Presentation
December 2022

Disclaimer
This presentation was prepared for informational purposes only by Moolec Science Limited, (“Moolec”) and LightJump Acquisition Corporation (“LightJump”) and is intended to be provided only to accredited institutional investors who are considering an investment in Moolec. The information
provided in this presentation is intended to highlight certain matters bearing upon the current status of Moolec that may be of interest to potential investors. The information is not complete, comprehensive or exhaustive, and any potential investor wishing to obtain additional information about
topics referenced in the presentation, or other matters in connection with a potential investment, is encouraged to contact Moolec.
Forward-Looking Statements
This presentation includes “forward-looking statements.” Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate
future events or trends or that are not statements of historical matters. For example, statements concerning the following include forward looking statements: the growth of Moolec’s business and its ability to realize expected results; the business model of Moolec relating to any partnerships,
commercial contracts, regulatory approvals or patent filings; the viability of its growth and commercial strategy; financial projections; the success, cost and timing of its product development abilities; the advantages and potential of Moolec’s technology and products, including in comparison tocompeting technologies and products; trends and developments in the industry; the addressable market; the contemplated transaction among Moolec and LightJump; Moolec’s addressable market; and the potential effects of the business combination among Moolec and LightJump. Such forwardlooking statements with respect to performance, prospects, revenues and other aspects of the business of Moolec or LightJump are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks anduncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this presentation, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. These factors include, but are not limitedto: (1) the inability to complete the transactions contemplated by the proposed business combination, resulting in a combined company with the expectation to be listed on Nasdaq (the “Combined Company”); (2) the inability to recognize the anticipated benefits of the proposed businesscombination, which may be affected by, among other things, competition, and the ability of the combined business to grow and manage growth profitably; (3) the inability to successfully retain or recruits officers, key employees, or directors following the proposed business combination; (4)effects on LightJump’s public securities’ liquidity and trading; (5) the market’s reaction to the proposed business combination; (6) the lack of a market for LightJump’s securities; (7) Moolec’s and LightJump’s financial performance following the proposed business combination; (8) costs related tothe proposed business combination; (9) changes in applicable laws or regulations; (10) the possibility that LightJump or Moolec may be adversely affected by other economic, business, and/or competitive factors; (11) the risk that Moolec is unable to successfully develop and commercialize
Moolec’s products or services or experience significant delays; (12) the risk of product liability or regulatory lawsuits relating to Moolec’s products and services; (13) the risk that Moolec is unable to secure or protect its intellectual property; (14) the ability to maintain the listing of LightJump’s
securities on Nasdaq and (15) the ability for the Combined Company’s securities to be approved for listing on Nasdaq or if approved, maintain the listing. The foregoing list of factors is not complete or exhaustive. You should carefully consider the foregoing factors as well as other risks anduncertainties described in the “Risk Factors” section of LightJump’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in the final prospectus of LightJump related to its initial public offering filed with the Securities and Exchange Commission (“SEC”). You should also carefully
consider the other risks and uncertainties indicated from time to time in documents filed or to be filed with the SEC by LightJump and the Form F-4 and proxy statement to be filed with the SEC by the Combined Company and LightJump.
Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Forward-looking statements speak only as of the date they are made. Accordingly, you should not put undue reliance on these statements.
Industry and Market Data; Trademarks and Trade Names
In this presentation, Moolec and LightJump rely on and refer to information and statistics regarding the market in which Moolec competes and other industry data. Moolec and LightJump obtained this information and statistics from third-party sources, including reports by market research firms.
Accordingly, none of Moolec, LightJump nor their respective affiliates and advisors makes any representations as to the accuracy or completeness of these data. Moolec and LightJump have supplemented this information where necessary with information from Moolec’s own internal estimates,
taking into account publicly available information about other industry participants and Moolec’s management’s best view as to information that is not publicly available. Moolec and LightJump also own or have rights to various trademarks, service marks and trade names that they use inconnection with the operation of their respective businesses. This presentation also contains trademarks, service marks and trade names of third parties, which are the property of their respective owners. The use or display of third parties trademarks and Moolec or LightJump use thereof does not
imply an affiliation with, or endorsement by the owners of such trademarks, copyrights, logos and other intellectual property. Solely for convenience, the trademarks, service marks and trade names referred to in this presentation may appear without the ®, TM or SM symbols, but such references are
not intended to indicate, in any way, that Moolec or LightJump will not assert, to the fullest extent under applicable law, their rights or the right of the applicable licensor to these trademarks, service marks and trade names. Moolec takes all necessary action to respect all intellectual property rights.
No Offer or Solicitation
This presentation is for informational purposes only and is neither an offer to purchase, nor a solicitation of an offer to sell, subscribe for or buy any securities or the solicitation of any vote in any jurisdiction pursuant to the proposed transactions or otherwise, nor shall there be any sale, issuance ortransfer or securities in any jurisdiction in contravention of applicable law. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act.
Confidentiality
All recipients agree that they will keep confidential all information contained herein and not already in the public domain and will use this presentation solely for evaluation purposes. Recipient will maintain all such information in strict confidence, including in strict accordance with any underlying
contractual obligations and all applicable laws, including United States federal and state securities laws. This presentation is not intended to constitute and should not be construed as investment advice and does not constitute investment, tax, or legal advice.
Important Information About the Business Combination and Where to Find It
In connection with the proposed transaction, the Combined Company, which is expected to become the holding company of LightJump and Moolec as of the closing of the proposed transaction, filed a registration statement on Form F-4 (the “Form F-4”) with the SEC that includes a proxystatement of LightJump that will also constitute a prospectus of the Combined Company. Moolec, the Combined Company and LightJump urge investors, stockholders and other interested persons to read, when available, the Form F-4, including the preliminary proxy statement/prospectus andamendments thereto and the definitive proxy statement/prospectus and documents incorporated by reference therein, as well as other documents filed with the SEC in connection with the proposed transaction, as these materials will contain important information about Moolec, the Combined
Company, LightJump and the proposed transaction. After the registration statement is declared effective, the definitive proxy statement/prospectus to be included in the registration statement will be mailed to shareholders of LightJump as of a record date to be established for voting on the
proposed business combination. Once available, shareholders will also be able to obtain a copy of the Form F-4, including the proxy statement/prospectus, and other documents filed with the SEC without charge, by directing a request to: 2735 Sand Hill Road, Suite 110, Menlo Park, CA 94025. The
preliminary and definitive proxy statement/prospectus to be included in the registration statement, once available, can also be obtained, without charge, at the SEC’s website (www.sec.gov).
Participants in the Solicitation
Moolec and Lightjump and their respective directors and executive officers may be considered participants in solicitation of proxies with respect to the proposed business combination described in this presentation under the rules of the SEC. Information about the directors and executive officersof LightJump is set forth in LightJump’s final prospectus filed with the SEC pursuant to Rule 424(b) of the Securities Act of 1933, as amended (the “Securities Act”) on January 12, 2021, and is available free of charge at the SEC’s website at www.sec.gov or by directing a request to: 2735 Sand Hill
Road, Suite 110, Menlo Park, CA 94025. Information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of the LightJump stockholders in connection with the proposed business combination will be set forth in the registration statement containing
the proxy statement/prospectus for the proposed business combination when it is filed with the SEC. These documents can be obtained free of charge from the sources indicated above.

SCIENCE IN
ALTERNATIVEPROTEINS.02

Planting the Future of Food
Moolec is a science-based
food ingredient company
focused on the use of
Molecular Farming
technology.
Our purpose is to upgrade taste, nutrition, andaffordability of alternative protein products
while building a more sustainable and equitable
food system.

SCIENCE IN
ALTERNATIVEPROTEINS.03

Business Model
Moolec's innovation starts at the beginning of the food value chain.

Modiﬁed
Seeds

Contracted
Growers &Downstream

Plant-based
Animal Protein
Ingredients

B2B
Model

Food
Producers &CPG
Companies

Retail / Food
Services

Consumers

Moolec’s IP

IngredientCompanies
Partnership or Licensing

SCIENCE IN
ALTERNATIVEPROTEINS.04

Moolec's Operations
We operate through hubs in established locations where cutting-edge R&D and science
services are provided, and optimal natural conditions for crop development are present.

Food Science
Hub

Crop Science& Cultivation
Washington
State University

WISCONSIN CROPINNOVATION CENTER

Industrial
Hub

Molecular
Biology

Back Office& Cultivation

SCIENCE IN
ALTERNATIVEPROTEINS.05

World Class Management TeamTop Ph.Ds and recognized professionals that come from all over the worldconform Moolec’s team in line with our global ambitions and targeted footprint.

Gastón Paladini, MBA
Chief Executive Officer

Henk Hoogenkamp, Ph.D
Chief Product Officer

Amit Dhingra, Ph.D
Chief Science Officer

20+ years in marketing and the
traditional food industry as a
Director of Paladini Group, oneof the largest meat production
players in Argentina.

15 years in food andbio-materials applications withspecial focus on animal andplant-based proteins.

20+ years in genomics and plantbiotechnology. Prof. and Head,
Department of Horticultural
Sciences, Texas A&M University.
10+ years of corporate leadership.

David Heron, Ph.D
Regulatory Affairs
30+ years in the biotechnology
regulatory program of USDA-APHIS
focused on policy development,
training, public communication, andcapacity building in agricultural
biotechnology.

SCIENCE IN
ALTERNATIVEPROTEINS

Martín Salinas, Ph.D
Chief of Technology

Catalina Jones, B.A.
Chief of Staff & Sustainability

15 years in strategic roles for
multinational companies inagribusiness and tech withexpertise in ﬁnance, strategy, andpartnerships.

15+ years in engineering and Ag-biotech
space leading the world’s ﬁrst industrial
production of animal protein inplants for the food industry.

10+ years in communications,accountability, and sustainability
management for ﬁnancial,agribusiness, packaging, and foodindustry.

Martín Taraciuk, M.Fin
Investor Relations

Bruce Williamson, Ph.D
Sr. Plant Biologist

Vivek Narisetty, Ph.D
Sr. Molecular Biologist

8+ years in investor relations roles
for public listed companies in realestate, agribusiness and energy,
capital market transactions,ﬁnance, M&A, valuations,and corporate ﬁnance.

10+ years of researchexperience and a strong
background in molecular plantsciences, plant breeding, andbiotechnology.

7+ years in processdevelopment for value-added
chemicals, strain and media
engineering, bioreactor scale-up
and downstream processing.

José López Lecube, MBA
Chief Financial Officer.06Pro-Forma Ownership1

2

100.0%

3

The Biotech 4
Company LLC
20.0%

80.0%

BG Farming
Technologies Ltd.
(NASDAQ:BIOX)

37.0%

4.7%

New Company
Shareholders6

5

37.0%

3.8%

Other 8Investors

LJAQ Public
Stockholders

InitialStockholders 7
6.5%

7.0%

3.9%

9

Pre de-SPAC shareholders

1 Assumes no LJAQ Public Stockholders exercise redemption rights in connection with the business

SCIENCE IN
ALTERNATIVEPROTEINS

combination; actual redemptions may differ. For a complete description of all the assumptions applicableto this chart, please refer to "Appendix - Latest Detail Pro-Forma Ownership"
2 Bioceres Group PLC
3 Bioceres Group venture vehicle
4 Moolec Science Ltd. CEO Holdco
5 Refers to Union Group Ventures Ltd.

New Shareholders

6 Reflects certain shareholders of Bioceres S.A. and Bioceres Group PLC that will receive a new issuance of Company

Ordinary Shares, prior to the business combination, that will be exchanged for Holdco Ordinary Shares

7 Refers to LJAQ Sponsor shares and ordinary shares issued to EarlyBird in connection with the IPO

8 Includes shares from Moolec SAFE holders that entail Theo I SCSp, third-party investors, and shares from other equity

commitments

9 Moolec Science SA, the combined company following the completion of the business combination.07

Moolec by the Numbers
The company is pioneering the future of alternative protein
production with Molecular Farming technology.

st
1

$65B

20+

Total Addressable Market(2025E)1

Team to achieve a bovine
protein with plants for food2

Global Patents &Patent Applications3

60x

35x

100%

Less GHG Emissions
vs. Cattle Farming4

Less Land Usage vs.
Cattle Farming5

10+

4

Years of Propietary
Research & Development2

Key Alliances with crop scienceand pharmaceutical players

1 Moolec's internal analysis based on publicly disclosed information for the industry, primarily the GFI State of Industry Report 2021 (March 2022)

SCIENCE IN
ALTERNATIVEPROTEINS2 This milestone was achieved by a Team within Bioceres Group, Moolec's predecessor company

3 Both granted and pending

4 https://ourworldindata.org/food-choice-vs-eating-local

5 https://ourworldindata.org/agricultural-land-by-global-diets

Cruelty-Free

8

Signed Contracts, MOUs &MTAs with Food Producers.08

A spin-off from Bioceres Group
Bioceres transferred full ownership of patents and 10+ years experience in Molecular
Farming technology to form a standalone, food-science-focused company.

Science for asustainable agriculture

Science applied toalternative proteins
Scientific Team
+Intellectual Property(Bioceres S.A.
Private entity)

SCIENCE IN
ALTERNATIVEPROTEINS

Newly formed management
and scientific leadership.09

Moolec’s Pathway to Public Listing
10 years building our technology
Lab
Pilot plant

SPC Patents
Approvals

Industrial
Scale

2008

2014

2018

Technology scale-up
From Safflower
to SoySpin-off(UK Entity)

2020

Company
Building

Expected
Listing

2021

2022

GLA IP Incorporation
Proof of Concept(Bioceres S.A. - Private entity)

SCIENCE IN
ALTERNATIVEPROTEINS(NASDAQ:BIOX).10

Backers & Partners
Moolec's shareholders and strategic partners bring key experience, advisory,
scientiﬁc know-how, and access to facilities to strengthen the business.

Science + Operations

Finance

Strategic Joint Venture

Provider of ag-tech solutions enabling
the transition towards carbon neutrality• Facilities, Fields & Farmers• IP + Legal Team• Tech Services

Molecular Biology + Scale Up• Union Group is a privately owned
invest-ment and private equity
management ﬁrm established in 2007.
These cover the agricultural, energy,
forestry, infrastructure, minerals, oil &gas and real estate sectors.

• Global presence• Commitment in developing longterm, innovative, and sustainableprojects.
• Business:o Life Scienceso Information & Cultureo Agribusinesso Nature & Design

SCIENCE IN
ALTERNATIVEPROTEINS.11

Why Moolec?

01

02

03

04

05

06

Category creators: science-based& high-value added company pioneerof the 4th technological pillar within
the alternative protein industry.

Highly experienced team:visionary leadership teamwith unparalleled expertise in the
Molecular Farming category,ingredients, and food industry.

SCIENCE IN
ALTERNATIVEPROTEINS

1 Refers to Total Addressable Market

Massive addressable market:
sizeable TAM1 and industry trends
support signiﬁcant growth
opportunities.

ESG pure play: Moolec works
towards 10 out of the 17 the SDGs
within an industry that creates anenvironmentally positive impact.

Unmatched value proposition:
advantages include lower cost,higher scale, and betterorganoleptic experience.

Long-standing backers: endorsedby leading companies in biotech &life sciences, finance, and molecularbiology.

.12

The Industry

Food Crisis: Ring of Fire
Weakness of global food supply chain is on the spotlight due to present context.

Economic1

Environmental3• War in Ukraine isamplifying global
food crisis2.

• Rising average global
climate temperature andextreme weather
patterns are expected tocontinue.

• 25.9% of the global
population experiences
hunger or does not haveregular access to nutritious
and sufficient food6.

• The $100B toll of a pig
epidemic in China. African
Swine Fever in China isshaking up world trade
ﬂows8.

• 70% of all freshwater isalready dedicated to
traditional agriculture4.

• $1.7tn in annual economic
cost of diet-related illness
in US.

• WHO says that overuse ofantibiotics in farming
contributes to higher
levels of its resistance insome human infections9.

• World Bank expects
upward pressure oncommodity andagriculture prices tocontinue.

SCIENCE IN
ALTERNATIVEPROTEINS

1 https://www.fao.org/worldfoodsituation/foodpricesindex/en/
2 https://time.com/6162598/ukraine-war-food-shortage/

Nutrition5

3 https://www.mckinsey.com/~/media/mckinsey/industries/agriculture/our%20insights/reducing%20agriculture%20emissions%20through%20improved%20farming%20practices/agriculture-and-climate-change.pdf
4 https://www.worldbank.org/en/topic/water-in-agriculture#1

Pests & Diseases7

5 https://milkeninstitute.org/report/americas-obesity-crisis-health-and-economic-costs-excess-weight6 https://www.who.int/docs/default-source/nutritionlibrary/publications/state-food-security-nutrition-2020-inbrief-en.pdf7 https://www.fao.org/news/story/en/item/1402920/icode/

8 https://gro-intelligence.com/insights/how-african-swine-fever-in-china-is-shaking-up-world-trade-flows
9 https://www.saveourantibiotics.org/the-issue/antibiotic-overuse-in-livestock-farming/.14

Food System Overview

1

Animals

Soybean:Billions

PlantsPeople87
6Animal welfare claimed
to be the one of themost important factors
for consumers

Global Meat
Products Market:$1 trillion

most consumed
meat analogue
with the highest
protein content

Human population
since 1800

5
4
3
2
1

USA & Argentina
among the top 3
countries of soybean
producers worldwide

+
25 kg
Grain

=
15.400 lts
of waterFeed to foodconversion
inefficiency

1 kgof meatGreenhouse
Gas Emissions (GHG)
from average
food consumption

5%

4%

47%

19%

1 Sources:

SCIENCE IN
ALTERNATIVEPROTEINS

•
•
•
•
•
•
•
•

Meat
Dairy production
Poultry, fish, seafood, and eggs
Sugars, oils, and fats
Vegetables
FruitsGrain Products
Others7%
14%

FAO. The Contribution of Agriculture to Greenhouse Gas Emissions (February 2020)
https://ahdb.org.uk/news/consumer-insight-understanding-consumers-attitudes-to-animal-welfare
https://ask.usda.gov/s/article/What-is-the-most-consumed-meat-in-the-world
https://ourworldindata.org/meat-production
https://ourworldindata.org/meat-production#global-meat-production
https://population.un.org/wpp/
https://sniglobal.org/
https://www.fao.org/in-action/sustainable-and-circular-bioeconomy/resources/news/details/en/c/1459357

1750

1800

1850

1900

1950

2000

2050
Years

Highest population growth expected
in developing countries with low GDP per capita

3% 1%

77% of soybean
production ends
as feed for livestock
for meat and dairy
production

0

Healthy diets are 5 times more expensive
than diets that meet minimum energy levels

Today

22%

Consumers are vegetarian, vegan or
ﬂexitarians and growing

https://www.foodnavigator.com/News/Promotional-Features/Taste-texture-and-nutritional-attributes-of-alternative-protein-products
https://www.un.org/en/academic-impact/97-billion-earth-2050-growth-rate-slowing-says-new-un-population-reporthttps://www.usda.gov/oce/commodity/wasde/wasde0922.pdf
https://www.who.int/docs/default-source/nutritionlibrary/publications/state-food-security-nutrition-2020-inbrief-en.pdf
RethinkX. Rethinking Food and Agriculture 2020-2030. The Second Domestication of Plants and Animals, the Disruption of the Cow, and the Collapse ofIndustrial Livestock Farming• WWF & SustainAbility. Sustainable Food Systems and Diets: This review of multi-stakeholder initiatives (October 2018)• https://www.researchandmarkets.com/reports/5633454/meat-products-global-market-opportunities-and?
utm_source=GNOM&utm_medium=PressRelease&utm_code=hfbkjw&utm_campaign=1739586+-+Global+Meat+Products+Market+Analysis%2c+Opportunities%2c+Forecasts%2c+and+Strategies+2016-2021%2c+2021-2026%2c+%26+2026-2031&utm_exec=chdo54prd
•
•
•
•
•

.15

Total Addressable Market

1

Massive opportunity to play in a double-digit growing industry (17% CAGR).

90%

$300B
72%

55%

$140B
$65B

$40B

45%

2030

2035

10%

2025

2022

Alternative Protein

SCIENCE IN
ALTERNATIVEPROTEINS28%

1 Sources:

Traditional Meat Consumption Share (%)

Alternative Meat Consumption Share (%)• Moolec’s internal analysis based on publicly disclosed information for the industry, primarily the GF1 State of Industry Report 2021 (March2022)• United Nations, W orld Bank, Expert Interviews, A.T. Kearney Analysis.16

Alternative Proteins Industry
Emerging industry where companies use different technologies and ingredients
based on plants, cells, and microbes to address the main food challenges.

Plant-Based

Fermentation

Cultured Meat

Products made from plants that arealternatives to animal-based products.
This includes plant-based meat,seafood, eggs, and dairy.

Use of intact live microorganisms tomodulate and process plant-derived
ingredient; the leverage of the fast
growth and high protein content of
microorganisms for efficient production.

Genuine animal meat produced bycultivating animal cells directly.
Made of the same cell types arranged in thesame or similar structure as animal tissues,
thus replicating sensory and nutritional
proﬁles of conventional meat.

1

SCIENCE IN
ALTERNATIVEPROTEINS2

1

https://gﬁ.org/science/the-science-of-plant-based-meat/2

https://gﬁ.org/science/the-science-of-fermentation/3

https://gﬁ.org/science/the-science-of-cultivated-meat/

3.17

Taste andtextureSCIENCE IN
ALTERNATIVEPROTEINS

Nutritional
valuesScalability
and low costs.18

The solution: Moolec as a Category Creator

1

Molecular Farming has the potential to overcome the main obstacles
faced by other technologies in the alternative protein landscape.

Plant-based

Fermentation

Cultured meat

Molecular Farming

Taste and texture

Nutritional values

Scalability and low costs

PlantsScience

Plants + Science

1 Sources:

SCIENCE IN
ALTERNATIVEPROTEINS

•
•
•
•
•
•

https://www.studyﬁnds.org/taste-plant-based-diet/https://www.foodnavigator-asia.com/Article/2021/08/17/Plant-based-nutritional-pitfalls-Why-novel-products-don-t-necessarily-improve-diet-quality-Study
https://www.morningstarfarms.com/content/dam/NorthAmerica/morningstarfarms/pdf/MSFPlantBasedLCAReport_2016-04-10_Final.pdf
https://link.springer.com/article/10.1007/s11367-015-0931-6
https://thecounter.org/lab-grown-cultivated-meat-cost-at-scale
https://gﬁ.org/wp-content/uploads/2021/03/cultured-meat-LCA-TEA-policy.pdf.19

Molecular Farming Ecosystem

1

The industry is growing with stronger recognition of the advantages of Molecular Farming.
Moolec is the only player focused on growing meat proteins in both soy and pea seeds.

Nobell Foods2

Dairy proteins in soybeans

PoLoPo5

Dairy proteins in potatoes

Miruku3

Dairy proteins in soybeans

VelozBio4

Dairy proteins in discarded fruit

Mozza6

Dairy proteins in plants

Tiamat Sciences8

Core Biogenesis9

Growth Factors

Growth Factors

ORF Genetics10

BioBetter11

Meat proteins in soybeans & pea

Kyomei7

Meat proteins in green leaves

Dairy proteins in Soybean
Growth Factors

Dairy
SCIENCE IN
ALTERNATIVEPROTEINSMeat

1 Moolec's internal analysis based on publicly disclosed information for the industry andmanagement estimates

6 https://www.mozzafoods.com/

2 https://www.nobellfoods.com/

8 https://www.tiamat-sciences.com/

3 https://miruku.com/

4 https://velozbio.com

5 https://www.linkedin.com/company/polopo/about/Growth Factors

Growth Factors12

7 https://kyomei.co.uk/

9 https://corebiogenesis.com/

10 https://www.orfgenetics.com/
11 https://biobetter.bio/
12 Substance which is required from Cultured Meat Technology for the stimulation of growth in living cells.20

The Technology

Animal Proteins in Plants
Moolec introduces real animal genes in the plant's genome
to give real taste and nutrition to food.

Traditional

Seeds

Crops

Livestock

Feed

Food
ed animal proteins
Plant-bas

Molecular
Farming

Seeds

Crops

Cruelty-Free
Food

g
Anima
n
i
r
e
e
n
l proteins - Genetic engi

SCIENCE IN
ALTERNATIVEPROTEINS.22

Molecular Farming: a cost-effective way
1
to produce alternative proteins

SCIENCE IN
ALTERNATIVEPROTEINS

1 Moolec's internal analysis based on publicly disclosed information for the industry and management estimates.23

Moolec vs. Animal-based Production System
Molecular Farming is more friendly to the environment
when compared to traditional protein productive systems.

1

SCIENCE IN
ALTERNATIVEPROTEINS

1 https://ourworldindata.org/agricultural-land-by-global-diets

8X less2

2 https://waterfootprint.org/en/water-footprint/product-water-footprint/water-footprint-crop-and-animal-products/

3 https://ourworldindata.org/food-choice-vs-eating-local

3.24

Molecular Farming in a Nutshell

Selection

Transformation

.01

.03

Real DNA(protein ofinterest) is isolated.02

SCIENCE IN
ALTERNATIVEPROTEINS

Production

Engineered
cells grow into
whole plants

Seeds areharvested andcrushed.07.05

Vector isinserted into plant
chromosomes
Gene isinserted into
expression vector

Development
Scale-Up

Cells expressing
the desired proteins
are selected andgrown into cultures.04

Plants grow ﬁrst
in greenhouses andthen at the ﬁelds

Plant-based
Animal Protein
Ingredients

.06

.08

.25

Proof of Concept: Why Chymosin?
Chymosin is a validation molecule in biotechnology by being the ﬁrst
protein for food been approved by the FDA with precision fermentation

90’s

Fermentation2010

Molecular Farming

Plant-Based Bovine Protein
Safflower
Crops
Safflower
Seeds

Bovine Gene

Cheeseingredient

Molecular Farming“Groundbreaking Moment for Biotechnology”

SCIENCE IN
ALTERNATIVEPROTEINS

1

Moolec’s team achieved the same with plants1

This milestone was achieved by a Team within Bioceres Group, Moolec's predecessor company.26

Transferrable & scalable technology
Based on our Proof of Concept we were able to extend
our technology to new hosts with enhanced features.

Soy proteins+
Plant-Based
Chymosin

SCIENCE IN
ALTERNATIVEPROTEINS

Meat Proteins

Safflower

Soy

Protein content

20%

40%

Scalability

120K has

50M hasYield

1 ton/ha

5 ton/haMarket

350M Chymosin

1.5B Meat Replacement.27

Fermentation: Our Validation Platform
Precision fermentation complements Molecular Farming technology
as validation stage and faster go-to-market pathway.

Fast application testing
Quick regulatory footprint
IP discovery

Technological Strategy
Validation Stage / Low Scale

Partnerships and commercial
opportunities
Product development

Expansion Stage / High Scale

Stage 2: Molecular Farming

Stage 1: Fermentation - Strategic Joint Venture

SCIENCE IN
ALTERNATIVEPROTEINS.28

Pipeline & Products

Pipeline Status
R&D
PROGRAMHOSTPROJECT

PLANED

PROOF OFCONCEPTEARLY
DEVELOPMENTADVANCED
DEVELOPMENT

PRE-LAUNCHPRODUCTLAUNCHLAUNCH

Meat
Replacement(POORK+& BEEF+)STATUS

SAM2
2025

SPC2

-

2025

350M3

GLASO

-

2025

1.5B4

YEEA1

1

2025

YEEA2

1

2025

YEEA3

2

2026

SOOY1

3

2027

SOOY2

3

2029

SOOY3

3

2029

SOOY4

4

TBD

PEEA1

3

2028

Safflower

Yeast

REGULATIONCOMMERCIAL

PHASE1DISCOVERY

Dairy ingredient andNutritional oil(Chymosin & GLA)OPERATIONS

1.5B5

SoybeanPea

SCIENCE IN
ALTERNATIVEPROTEINS

1 Refers to different phases of meat replacing process
2 Serviceable Available Market

3 Moolec internal analysis based on Global Rennet Market 2022-2027 - Mordor Intelligence4 Moolec internal analysis based on Global Gamma Linolenic Acid market. Market size, status and forecast to 2028 - Verified Market Research
5 Moolec internal analysis based on Plant-based Ingredients Market 2021 - MarketsAndMarkets.30

Plant-Based Meat
1
Ingredients by Weight

Flavouring& Appearance

5%
5%

Alternative meat industry still uses traditional
ingredients, limiting it from overcoming major
challenges and meeting consumer expectations.

Binding& Texturizing

20%

Plant
Proteins

50%

Water

20%

Current industry
challenges
Not clean label. 20+ different components

Sunﬂower& Coconut
Oils

Not fully natural. Synthetic and chemical additives
Not the same nutritional values to animal-based

SCIENCE IN
ALTERNATIVEPROTEINS

1 Sources:• Bakhsh, A.; Lee, S.‐J.; Lee, E.‐Y.; Hwang, Y.‐H.; Joo, S.‐T. Characteristics of Beef Patties Substituted by Different Levels of Textured Vegetable Protein and Taste Traits Assessed by Electronic
Tongue System. Foods 2021, 10, 2811. https://doi.org/10.3390/foods10112811• Annotated with internal analysis of nutritional data of market available products (NL).

.31

Moolec's Substitute Process by Cost

1

PHASE 1PHASE 2
PHASE 3%50uring

Texturizing

+ 14%
Plant

Proteins=+ 20%
Sunﬂower& CoconutOils

99%of the
cost

1%

Water

Current industry
challenges

With Moolec’sTechnology

Not clean label. 20+ different components

Clean label approach

Not fully natural. Synthetic and chemical additives

Real animal protein genes

Not the same nutritional values to animal-based

Healthier nutritional values

Sunﬂower& Coconut
Oils

PH
A
SE
4
SCIENCE IN
ALTERNATIVEPROTEINS

1 Phases included refer to the information displayed on Slide 30. Moolec takes all necessary action to respect all intellectual property rights.

14%

15%

Binding& Texturizing

PHASE
2

20%

Plant
Proteins

3+ 15%
Binding &Flavo& Appearance

E
AS
PH

50%
Flavouring &Appearance

PHASE 1PHASE 4.32

Enhanced plant-based ingredients with real animal proteins inside1.

POORK+BEEF+

SOY+PORKPEA+BEEF

CRUELTY-FREE

CRUELTY-FREE

Safflower
Soy

Pea

Dairy Ingredient

Nutritional Oil

Meat Replacement

Meat Replacement

Plant-based chymosin, a
key ingredient for cheese
production compulsory
for the clotting step.

Plant-based GLA oil
destined for enriching
food, nutraceuticalproducts, and pet food2.

Plant-based real porcine
proteins embedded within thematrix of native soy proteinsto enhance alternative meatproducts.

Plant-based real bovine
proteins embedded within thematrix of native pea proteinsto enhance alternative meatproducts.

Nutrition3

Sensory4/Nutrition3

Sensory4/Nutrition3

Texture1 Applies to plant-based Chymosin, POORK+ and BEEF+ products. GLA is a plant-based nutritional oil

SCIENCE IN
ALTERNATIVEPROTEINS

2 The FDA has approved the GLA-containing safflower seed oil as a new ingredient in dietary supplements, nutritional beverages, and medicinal foods for humans. The FDA has also

approved the use of the seed oil as an ingredient in dog and cat food and the use of the seed meal in cattle and poultry feeds. Moolec is conducting pre-submission consultation with
the FDA with respect to additional uses in food products for humans and animals
3 Nutrition can refer to a superior digestibility of the expressed protein or any improved micronutrient content and subsequent bioavailability
4 Sensory implies an improved perception after inclusion into the formulation of a speciﬁc food product such as meat replacers.33

Today most consumers accept GMO Food
98% of all soybeans grown in the USA are GMO, and Impossible Burger's successful rollout
conﬁrmed that GMO is no longer a material issue in the US consumer's minds1,2.

Transparency
and the cause's
purpose are key
Discussion gravitatesaround science, hunger
and climate change.
Moolec promotes a newscientiﬁc movement3:

SCIENCE IN
ALTERNATIVEPROTEINS

1 https://www.fooddive.com/news/gmo-labeling-not-likely-to-impact-purchase-decisions-study-says/616452/

2 https://allianceforscience.cornell.edu/blog/2022/03/anti-gmo-themes-losing-traction-worldwide-suggests-new-scientific-paper/
3 https://gm4good.org/.34

Regulatory Pathway
Moolec is subject to the laws and regulations governing biotechnology
and food companies in the jurisdictions in which we operate.

Regulation of Plant
Biotechnology Products

Regulation of Foodand Ingredient Products

Other Regulatory
Requirements

Subject regulations andrequirements related to:• Safe working conditions• Laboratory and distribution practices• Transportation• Disposal of hazardous or potentiallyhazardous substances• Cross-border transit of ﬁnished goods
and raw materials

SCIENCE IN
ALTERNATIVEPROTEINS.35

Patent PortfolioA
D P TENTE
TE
N

D

PAT
E

Moolec stands on a strong and growing IP strategy with great understandingof the biotech landscape offering a competitive advantage on its execution.

D PATENTE
TE
N

D

PAT
E

NTED
PATE

G
PENDIN
T
N
E
T
PA

TION
PPLICAA
T
N
E
PAT

SCIENCE IN
ALTERNATIVEPROTEINS

GLA

Chymosin
SPC

New
Filings

17 Patents
3 Patents
Australia

United States

MexicoJapan

CanadaBrasilArgentina

New Zealand

Italy

Germany

Spain

China

FranceUK

Hong Kong

Malaysia

Australia

United States

MexicoCanadaBrasilArgentina

Italy

Germany

FranceUK

2 Patents
United States.36Latest Milestones
Soybean

T1 seed harvested. Next phase for achieving
T2 & T3 seeds started August 2022

Pea

Ongoing transformation
and regeneration stage

Chymosin SPC
Planted in Córdoba,
Argentina June 2022

Sampleof seedproteinextract
expressing
proteinof interest

GLA

Planted in Idaho Falls, USA,harvested October 2022

SCIENCE IN
ALTERNATIVEPROTEINS

SPC x GLA

Back Crossing 1 ﬁnished.
Back Crossing 2 started June 2022

Fermentation platform

1st yeast-based prototype for meaty ﬂavor.37

Environmental, socialand governance (ESG)Moolec addresses directly 10 of the 17 SDGs
We use SDGs and 2030 Agenda as guidelines to strategically align our business inthe search of the building of a more equitable, resilent and sustainable food system1,2.

From ending poverty,
hunger to responding toclimate change, foodand agriculture lie at thevery heart of the 2030
Agenda for Sustainable
Development.

SCIENCE IN
ALTERNATIVEPROTEINS

1 https://sdgcompass.org/
2 http://www.fao.org/documents/card/en/c/09a43cf2-c53a-40fe-bf4aa7f87236b2ce/.39

Enviromental & Social Impact

1

Moolec’s technology is much more friendly to the environment and promotes
an inclusive global value chain, bringing farmers back to the equation.

Main Concept

Fermentation

Cultured meat

Molecular Farming

Water usage

Medium High

MediumLow

Energy eﬁciency

Low

Low

High

GHG Emisions

High

High

Low

Carbon capture

Negative

Negative

Positive

Workforce inclusion

MediumLow

High

1 Sources:

SCIENCE IN
ALTERNATIVEPROTEINS

•
•
•
•
•
•

https://www.studyﬁnds.org/taste-plant-based-diet/https://www.foodnavigator-asia.com/Article/2021/08/17/Plant-based-nutritional-pitfalls-Why-novel-products-don-t-necessarily-improve-diet-quality-Study
https://www.morningstarfarms.com/content/dam/NorthAmerica/morningstarfarms/pdf/MSFPlantBasedLCAReport_2016-04-10_Final.pdf
https://link.springer.com/article/10.1007/s11367-015-0931-6
https://thecounter.org/lab-grown-cultivated-meat-cost-at-scale
https://gﬁ.org/wp-content/uploads/2021/03/cultured-meat-LCA-TEA-policy.pdf.40Focused on using all parts of the plants

1

We create sustainable products and by-products following
circular supplies and resource recovery strategies2.
Plant & animal protein
for main product01

Leaves for carbon sequestrationand soil composting

05
02

Fiber as source forrenewable energy

04
03

SCIENCE IN
ALTERNATIVEPROTEINS

Oils as high-valued
by-productStarches for feed
and/or bioplastics

1 Information displayed in this chart is an example on what potential uses of the different parts of the plant can be destined for.

2

https://www.accenture.com/t20150523t053139__w__/us-en/_acnmedia/accenture/conversion-assets/dotcom/documents/global/pdf/strategy_6/accenture-circular-advantage-

innovative-business-models-technologies-value-growth.pdf.41

Appendix

Transaction Overview – Capitalization, Sources, and Uses
Transaction Sources and Uses

Pro–Forma Valuation

Redemptions Scenarios

Sources

0%

50%

100%

SPAC cash in trust1
Moolec shares (rollover equity)
8
Backstop$27.7 M
$325.0 M$0.0 M$13.8 M
$325.0 M$0.0 M$0.0 M$325.0 M$10.0 M

Total Sources$352.7 M$338.8 M$335.0 M

0%

50%

100%

Cash to Surviving Company Balance Sheet $16.0 M
Moolec shares (rollover equity)$325.0 M
2
Estimated transaction costs$11.7 M

$4.5 M$325.0 M$9.3 M$3.4 M$325.0 M$6.6 M

Total Uses

$338.8 M$335.0 M

Uses
1$352.7 M

Redemptions Scenarios

1, 3

Pro-Forma Shares Outstanding
Illustrative Share Price

MM shares$/sharePro Forma Equity Value

0%

50%

100%

39.3
$10.0

37.9
$10.0

37.69
$10.0

$393.3 M $379.5 M $375.6 M

1, 2(-) Pro-Forma Cash to Surviving Company Balance Sheet
7(+) Pro-Forma Net Debt-$16.0 M$0.0 M

Pro-Forma Enterprise Value$377.3 M $375.0 M $372.2 M

Pro–Forma Ownership1, 3-$3.4 M
$0.0 M

Redemptions Scenarios

MM Shares

Existing Shareholders4
LJAQ Public Stockholders
Initial Stockholders5
New Company Shareholders10
Other Investors6
Total-$4.5 M
$0.0 M

0%

50%

100%

31.0
2.8
2.5
1.5
1.5

78.7%
7.0%
6.5%
3.8%
3.9%

31.0
1.4
2.5
1.5
1.5

81.7%
3.7%
6.7%
4.0%
4.0%

31.3
0.0
3.0
1.5
1.8

83.3%
0.0%
8.1%
4.0%
4.8%

39.3

99.9%

37.9

100.1%

37.69

100.2%

1 Assumes different redemptions scenarios from LJAQ Investors consider that balance of the Trust Account was reduced from $138 M as of June 30, 2022, to $28 M as of July 12, 2022; actual redemptions may differ
2 Estimated transaction costs paid in cash (excludes expenses paid with equity); final expenses will differ depending on negotiations
3 Excludes private & public warrants, transaction costs paid with equity post-closing, and management equity plan

SCIENCE IN
ALTERNATIVEPROTEINS

4 Includes original Moolec shareholders
5 Refers to LJAQ Sponsor shares and ordinary shares issued to EarlyBird in connection with the IPO
6 Includes shares from Moolec SAFE holders that entail Theo I SCSp, third-party investors, and shares from other equity commitments
7 Assumes any existing debt will be canceled or prepaid at closing
8 LJAQ has entered into a backstop agreement with entities affiliated with Moolec to guarantee a $10M minimum cash condition at closing
9 Number of shares could differ depending on backstop agreement implementation

10 Reflects certain shareholders of Bioceres S.A. and Bioceres Group PLC that will receive a new issuance of Company Ordinary Shares, prior to the business combination, that will be exchanged for Holdco Ordinary Shares.43

Latest Detail Pro-Forma Ownership
Number of Shares

50%1

0%1

100%1, 2

BG Farming Technologies Limited

14,570,000

37.0%

14,570,000

38.4%

14,570,000

38.8%

Union Group Ventures Ltd.

14,570,000

37.0%

14,570,000

38.4%

14,820,0005, 8

39.5%

Bioceres Crop Solutions Corp.

1,860,000

4.7%

1,860,000

4.9%

1,860,000

5.0%

New Company Shareholders3

1,500,000

3.8%

1,500,000

4.0%

1,500,000

4.0%

262,260

0.7%

262,2600.7%

512,2606, 8

1.4%

Initial Stockholders4

2,535,000

6.5%

2,535,000

6.7%

8.1%

LightJump Public Stockholders

2,767,210

7.0%

1,383,605

3.7%

3,035,0007, 8-

0.0%

Key Staff Participation

232,5230.6%

232,5230.6%

232,523

0.6%

UG Holdings LLC

1,035,000

2.6%

1,035,000

2.7%

1,035,000

2.8%

Total

39,331,993

99.9%

37,948,388

100.1%

37,564,783

100.2%

Company SAFE Holders

1 Does not reflect any shares to be issued following Closing pursuant to (i) the EarlyBird Share Fee or (ii) any equity securities to be grantedpursuant to any management or employee share plans.
2 Assumes that the obligations under the Backstop Agreement are satisfied through a cash constribution to Holdco, including, (i) the Sponsor provides $5,000,000 in cash to Holdco, (ii) Union Group Ventures Ltd. provides $2,500,000 incash to Holdco and (iii)Theo I SCSp provides $2,500,000

SCIENCE IN
ALTERNATIVEPROTEINS

3 Reflects certain shareholders of Bioceres S.A. and Bioceres Group PLC that will receive a new issuance of Company Ordinary Shares, prior to the business combination, that will be exchanged for Holdco Ordinary Sharesin cash to Holdco.

4 Includes 2,415,000 held by the Sponsor and 120,000 ordinary shares issued to EarlyBird in connection with the IPO.

5 Reflects an additional 250,000 Holdo Ordinary Shares to be issued to Union Group Ventures Ltd. in connection with the BackstopAgreement.

6 Reflects an additional 250,000 Holdco Ordinary Shares to be issued to Theo I SCSp in connection with the Backstop Agreement.
7 Reflects anadditional 500,000 Holdco Ordinary Shares to be issued to Sponsor in connection with the Backstop Agreement.

8 In scenarios where a sufficient number of holders of Public Shares of SPAC Common Stock redeem their shares and the obligations under the Backstop Agreement are triggered, which would occur if theNet Available Assets minus the EarlyBird fee is less than $10,000,000, many variations of the ownership of Holdco Ordinary Sharespost-closing are possible

.44

w
e
r
e
a

fo
o

Let’s empower
science in foodfor the good of
the planet

k
e
c
r
a
s
.
dh

Follow us!
www.moolecscience.com